DiNardo, C. D., Foran, J. M., Watts, J. M., Stein, E. M., de Botton, S., Fathi, A. T., … Sallman, D. A. (2021). Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 21, pp. S346–S347).

DiNardo, Courtney D., James M. Foran, Justin M. Watts, Eytan M. Stein, Stephane de Botton, Amir T. Fathi, Gabrielle T. Prince, et al. “Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21:S346–47, 2021.

DiNardo CD, Foran JM, Watts JM, Stein EM, de Botton S, Fathi AT, et al. Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S346–7.

DiNardo, Courtney D., et al. “Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 21, 2021, pp. S346–47.

DiNardo CD, Foran JM, Watts JM, Stein EM, de Botton S, Fathi AT, Prince GT, Stein AS, Stone RM, Patel PA, Roboz GJ, Arellano ML, Erba HP, Pigneux A, Stuart RK, Thomas X, Uy GL, Lemieux IR, Zhang V, Kapsalis SM, Garcia-Manero G, Sallman DA. Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S346–S347.